Pharmaceutical Companies Propose Changes to Drug Discount Program Amid Privacy Concerns

Pharmaceutical companies Eli Lilly and Novo Nordisk have proposed changes to the 340B drug discount program that would require pharmacies to submit detailed patient data. Critics express concerns that this could compromise patient privacy and expose sensitive medical information. The companies argue the changes are necessary to prevent misuse of discounts, but the implications for data security remain a significant concern.